GHRH is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
Ireland, as of 2016, was the second-biggest per capita consumer of tea in the world, after Turkey. Local blends are the most common in Ireland, including Irish breakfast tea, using Rwandan, Kenyan and Assam teas. The annual national average of tea consumption in Ireland is 2.7 kg to 4 kg per person. Tea in Ireland is usually taken with milk or sugar and brewed longer for a stronger taste. Turkish tea is an important part of that country's cuisine and is the most commonly consumed hot drink, despite the country's long history with coffee. In 2004, Turkey produced 205,500 tonnes of tea (6.4% of the global total), which made it one of the largest tea markets in the world, with 120,000 tons being consumed in Turkey and the rest being exported. In 2010, Turkey had the highest per capita consumption in the world at 2.7 kg. As of 2013, the per-capita consumption of Turkish tea exceeds 10 cups per day and 13.8 kg per year. Tea is grown mostly in Rize Province on the Black Sea coast.
The structure of phylloquinone, vitamin K1, is marked by the presence of a phytyl sidechain. Vitamin K1 has an (E) trans double bond responsible for its biological activity, and two chiral centers on the phytyl sidechain. Vitamin K1 appears as a yellow viscous liquid at room temperature due to its absorption of violet light in the UV–visible spectra obtained by ultraviolet–visible spectroscopy. The structures of menaquinones, vitamin K2, are marked by the polyisoprenyl side chain present in the molecule that can contain four to 13 isoprenyl units. MK-4 is the most common form. The large size of vitamin K1 gives many different peaks in mass spectroscopy, most of which involve derivatives of the naphthoquinone ring base and the alkyl side chain.
Polysaccharide peptide (PSP) is a protein-bound polysaccharide extracted from the edible mushroom Coriolus versicolor. PSP is currently in the animal-testing phase of research in many countries for use as an anti-tumor drug. It appears to work as a biological response modifier (BRM), enhancing the body's own use of macrophages and T-lymphocytes, rather than directly attacking any tumors. Polysaccharide krestin (PSK) was first isolated in Japan in the late 1960s while PSP was isolated about 1983 in China. Each compound has shown remarkable anticancer properties with few side effects. By 1987 PSK accounted for more than 25% of total national expenditure for anticancer agents in Japan.
== Clinical trials == The drug was reported to improve motivation and reduce apathy in people with Parkinson's disease in a phase 2a clinical trial. As of September 2024, pirepemat is in phase 2 clinical trials for Parkinson's disease. A phase 3 trial is being planned. The drug was also under development for the treatment of "behavioral disorders" and attention deficit hyperactivity disorder (ADHD). However, no recent development for the former indication has been reported and development for ADHD was discontinued. In August 2020, pirepemat received an INNTooltip International Nonproprietary Name with a novel suffix reflecting its reputedly new and unique mechanism of action. Pirepemat is under development by Integrative Research Laboratories (IRLAB).
Sources: en.wikipedia.org
=== Mechanism of action === Fialuridine (FIAU) is thymidine-like nucleoside analogue that was investigated as an antiviral against hepatitis B virus (HBV). HBV replication depends on its viral polymerase, which acts as reverse transcriptase and makes viral DNA. Because FIAU-TP resembles the normal nucleotide TTP, the viral polymerase can use FIAU-TP as an alternative substrate during DNA synthesis. This disrupts replication in two related ways. Fist, FIAU-TP can directly inhibit hepatitis virus DNA polymerase activity (shown in the duck hepatitis B virus model). Second, FIAU-TP interferes with the early protein-priming stage of reverse transcription. In an in-vitro priming system, FIAU-TP caused premature termination of the short starter DNA, which prevents proper extension into full-length viral DNA. Importantly, FIAU is not a classic obligate chain terminator, because it still has an intact 3’-OH group. However, once FIAU is incorporated into the growing DNA strand, extension becomes strongly slowed or blocked after a short step, so it behaves as a ‘de facto’ chain terminator. So FIAU's antiviral action can be summarized as follows: after FIAU is converted inside the cell into the active triphosphate form FIAU-TP, it can be used by the viral polymerase during BHV reverse transcription. This interaction disrupts the priming step and subsequent DNA chain synthesis, which eventually reduces the formation of complete viral DNA genomes.
"Particles of dust or smoke in the atmosphere are essential for precipitation. These particles, called 'condensation nuclei,' provide a surface for water vapor to condense upon. This helps water droplets gather together and become large enough to fall to the earth which might affect the quality of our water if not for filters." Aerosol Ash (chemistry) Black carbon Carbon, basic component of ashes Carbon black Charcoal, carbon residue after heating wood mainly used as traditional fuel Cinereous, consisting of ashes, ash-colored or ash-like Coal, consisting of carbon as ash, and ash can be converted into coal Construction waste Dust | Fugitive dust Potash, a term for many useful potassium salts that traditionally derived from plant ashes, but today are typically mined from underground deposits
Uniform and genetically stable cultivars can be inadequate for dealing with environmental fluctuations and novel stress factors. Plant breeders have focused on identifying crops which will ensure crops perform under these conditions; a way to achieve this is finding strains of the crop that is resistance to drought conditions with low nitrogen. It is evident from this that plant breeding is vital for future agriculture to survive as it enables farmers to produce stress resistant crops hence improving food security. In countries that experience harsh winters such as Iceland, Germany and further east in Europe, plant breeders are involved in breeding for tolerance to frost, continuous snow-cover, frost-drought (desiccation from wind and solar radiation under frost) and high moisture levels in soil in winter. Breeding is not a quick process, which is especially important when breeding to ameliorate a disease. The average time from human recognition of a new fungal disease threat to the release of a resistant crop for that pathogen is at least twelve years.
Gastrointestinal side-effects (nausea, vomiting, diarrhoea) are common; the delayed-release formulation is meant to help overcome this problem. It is also a cause of drug-induced hepatitis. Patients with glucose-6-phosphate dehydrogenase deficiency should avoid taking aminosalicylic acid as it causes haemolysis. Thyroid goitre is also a side-effect because aminosalicylic acid inhibits the synthesis of thyroid hormones. Drug interactions include elevated phenytoin levels. When taken with rifampicin, the levels of rifampicin in the blood fall by about half. It is not known whether it will harm an unborn baby. With heat, 4-aminosalicylic acid is decarboxylated to produce CO2 and 3-aminophenol.
81. ArXiv [Preprint]. 2026 Jul 29:arXiv:2605.17186v2. Operator splitting for exploiting linear-rate closure in solving infinite ODE hierarchies. Chang JC. We introduce an operator-splitting method for infinite hierarchies of linear ordinary differential equations (ODEs) indexed by nonnegative integers. When the coupling coefficients depend linearly on the count index, an exact transformation closes the equations on finite count-index windows without an upper-boundary value. For more general hierarchies, Strang splitting applies the linear-rate closure during the linear-rate substeps and a conventional capped solver to the remainder. We derive the closure from generating functions and the method of characteristics and extend it to multi-indexed systems. The derivation requires neither positivity nor mass conservation, so it applies to a wider class of systems than the examplar stochastic models presented here. We discuss branching processes, stochastic predator-prey dynamics, the Schlögl chemical kinetics model, and a telegraph model for gene expression. Through numerical experiments and computational cost analyses we demonstrate that our operator splitting method is typically advantageous for solving large scale systems in terms of memory usage and computational time, while retaining accuracy competitive with finite state projection (FSP) methods. PMCID: PMC13618430
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.